March 22, 2022 5:27pm

The cell and gene therapy sector regained ground on Tuesday as I stated this a.m., “Volatility puts sector on notice regulating directional motion”

Financing: Applied Genetic Technologies (AGTC -$0.49 or -27.33% to $1.31) proposes offering

Pre-open indications: 5 Hits and 0 MISS

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts; compare two (2) sessions – Tuesday versus Monday

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +254.47 points (+0.74%); the S&P closed UP +50.43 points (+1.13%) while the Nasdaq closed UP +270.36points (1.95%)

 

Henry’omics:

U.S. stocks advanced Tuesday as investors continued to balance remarks from Fed Chair Powell alongside the ongoing war in Ukraine.

The moves follow a choppy session Monday that saw all three indexes plugged yesterday’s “deep dive” following last week's winning streak to close lower after Powell signaled the Fed was prepared to act more aggressively to rein in inflation.

 

This a.m.’s post, RegMed Investors’ (RMi) pre-open: “exposure to risk slips and slides. Volatility puts sector on notice regulating directional motion.” …  https://www.regmedinvestors.com/articles/12352

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened positive at 28 up/6 downs, 1 flat, stayed positive at the mid-day at 30/5 and 1 flat, ending with a positive close of 31/4;
  • Monday opened negative at 5 up/29 downs, 1 flat, stayed negative at the mid-day at 1/33 and 1 flat, ending with a negative close of 2/31 and 2 flats;

 

Pre-open Indications: 5 Hits < Biostage (BSTG -$0.17); SELL into Strength: Applied Genetic Technologies (AGTC -$0.50< Ionis Pharmaceuticals (IONS +$1.36,); BUY: Chinook Therapeutics (KDNY +$0.50), Sangamo Therapeutics (SGMO +$0.32)> 0 Miss >

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … 29 to date

 

Key Metrics:

  • Tuesday - Sector volume was LOW with 6 of the 31-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 1 of the 2-upside having higher than the 3-month average volume with LOW volume of 6 of 31-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +1.90% and the XBI was up +3.58%
  • Monday, the IBB was down -1.34% and the XBI was down -3.41%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.59 points or -1.51% at 22.94
  • Monday was down -0.29 points or -1.21% at 23.58

 

Jumping with share pricing momentum (15 of 31):

  • Beam Therapeutics (BEAM +$2.55 after Monday’s -$3.98),
  • Intellia Therapeutics (NTLA +$3.48 after Monday’s-$2.37),
  • Ultragenyx (RARE +$2.00 after Monday’s -$1.00),
  • CRISPR Therapeutics (CRSP +$1.84 after Monday’s -$2.23),
  • Global Blood Therapeutics (GBT +$1.52 after Monday’s -$0.44),
  • Alnylam Pharmaceuticals (ALNY +$1.40 after Monday’s -$2.82),
  • Ionis Pharmaceuticals (IONS +$1.36 after Monday’s -$0.33),
  • Sage Therapeutics (SAGE +$1.15 after Monday’s -$1.09),
  • Vericel (VCEL +$1.07 after Monday’s -$1.62),
  • Editas Medicine (EDIT +$1.07 after Monday’s -$0.95),
  • Caribou Therapeutics (CRBU +$0.87 after Monday’s -$0.62),
  • Regenxbio (RGNX +$0.69),
  • Chinook Therapeutics (KDNY +$0.50),
  • uniQure NV (QURE +$0.45),
  • Sangamo Therapeutics (SGMO +$0.32 after Monday’s -$0.39),

Hammered in today’s market (4 of 4):

  • Applied Genetic Technologies (AGTC-$0.49 after Monday’s -$0.08),
  • Biostage (BSTG -$ after Monday’s -$0.17),
  • Brainstorm Cell Therapeutics (BCLI -$0.05),
  • AxoGen (AXGN -$0.03),

 

March, Q1/2022:

  • Tuesday closed positive with 31 incliners and 4 decliners
  • Monday closed negative with 2 incliners, 31 decliners and 2 flats
  • Friday closed positive with 28 incliners and 5 decliners and 2 flats

 

The BOTTOM LINE: A come-back session, after a depressing Monday.

I am maintaining,” Caution is still in order.”

What and which go up, also slip down; it’s sector physiology as risks go both ways.

Last Friday ended on a high sector upside, Monday gave back gains and Tuesday feathered another upside move …

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.